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study demonstrated that non-adherence to atypical antipsychotics
leads to more hospitalizations and hospital days in the treatment
of schizophrenia.
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OBJECTIVES: To identify which patient baseline characteristics
and which types of early changes in patients’ clinical status are
most predictive of switching antipsychotics in the long-term
treatment of schizophrenia. METHODS: This post-hoc analysis
used data from a randomized, open-label, multi-site, one-year
cost-effectiveness trial of olanzapine, risperidone, and typical
antipsychotics in the treatment of schizophrenia. Study protocol
permitted switching of antipsychotics when clinically warranted.
Baseline characteristics were assessed using standard psychiatric
measures and systematic review of medical records. In addition
to baseline socio-demographics, co-morbid medical and psychi-
atric conditions, body weight, clinical, and functional character-
istics, the prediction model included change scores on clinical
measures (PANSS, ﬁve PANSS factor subscales, Barnes Akathisia
Scale, Simpson Angus Scale) during the ﬁrst two weeks of treat-
ment. Cox proportional hazards model was used to identify the
best predictors of switching from patients’ initial randomized
antipsychotic. RESULTS: About one-third (29.5%, 190/644)
switched antipsychotics before the end of the one-year trial. Five
variables were identiﬁed as best predictors of switching during
the 1-year trial (p < 0.05): absence of antipsychotic use in the
prior year, pre-existing depression, lack of lifetime substance use
disorder, less improvement or worsening following two weeks of
treatment on either clinician-rated akathisia (Barnes Akathisia
Scale), and/or anxiety/depression symptoms (PANSS). A strong
trend was observed for female gender (p = 0.058). CONCLU-
SIONS: Switching of antipsychotics appears to be prevalent in
the naturalistic treatment of schizophrenia, and can be predicted
by a small and distinct set of measures. Interestingly, pre-
existing depressive symptomatology and less improvement or
worsening of anxiety and depressive symptoms following two
weeks of treatment were among the more robust predictors of
future switching of antipsychotics in this one-year study.
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OBJECTIVES: To determine and compare the compliance and
persistence to typical and atypical antipsychotics in the treatment
of schizophrenia patients. METHODS: The study was based on
NC Medicaid claims database. Patients were included if they had
a diagnosis of schizophrenia (ICD-9 295.XX), received at least
two antipsychotic prescriptions during the period after index
date and were continuously enrolled in NC Medicaid Program
during three month prior and one year post treatment periods.
Medication possession ratio (MPR), persistence and medication
use gap were used as compliance measures. Both descriptive and
multivariate model were conducted to determine the difference
in adherence/persistence to antipsychotic medications between
typical and atypical antipsychotic. RESULTS: A total of 919
patients (469 in typical and 450 in atypical) met the selection
criteria for 3-month prior and 12-month after antipsychotic
treatment. There were statistically signiﬁcant differences between
typical and atypical antipsychotics in terms of demographics,
comorbidities, resource utilization in prior period, and adher-
ence. As compared with those in typical groups, patients in atyp-
ical group were signiﬁcantly younger (42.3 vs. 44.4, p = 0.0195),
less blacks (33.1% vs. 58.4%), had more comorbid diseases (2.7
vs. 2.3, p = 0.0025), more hospital visits (0.3 vs. 0.17, p = 0.002)
and greater total costs in prior period ($2703 vs. $2010, p =
0.012). The costs and utilization in prior period indicated that
patients in atypical groups were sicker than those in typical
groups. Patients in atypical group were more adherent to
antipsychotics (35.8% vs. 16.4%, p < 0.0001), less gaps (42.4%
vs. 67%, p < 0.0001), and stayed consistently in medication
longer (229 days vs. 146 days). CONCLUSIONS: The results
from this study indicated that there existed signiﬁcant differences
in terms of demographics, compliance and persistence between
typical and atypical antipsychotics in the treatment of 
schizophrenia.
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OBJECTIVES: To assess the clinical, functional, and economic
ramiﬁcations of switching antipsychotics for any cause during
treatment of schizophrenia. METHODS: We used outpatient
data from a randomized, open-label, one-year cost-effectiveness
trial of olanzapine, risperidone, and typical antipsychotics in the
treatment of schizophrenia. Study protocol permitted switching
of antipsychotics when clinically warranted. Resource utilization
was abstracted from medical records. Treatment outcomes were
assessed with standard psychiatric measures. Changes from pre-
to-post switch were assessed among patients who switched from
randomized antipsychotics. Switchers and non-switchers were
compared on risk for crisis-related events (e.g., hospitalization).
RESULTS: About one-third of the patients (30.2%, 185/612)
were switched from randomized antipsychotics: 14.9% from
olanzapine, 27.9% from risperidone, and 48.5% from typical
antipsychotics. Following antipsychotic switch, switchers expe-
rienced signiﬁcant improvements in symptoms and social rela-
tions (p < 0.001), and numerical cost reductions ($3.72 per day
less, p = 0.320). Compared to non-switchers, switchers were at
signiﬁcantly higher risk for crisis-related events (p = 0.006),
experienced them sooner (p = 0.004), and accrued higher 
crisis-related service costs (p < 0.05). CONCLUSIONS:
Although switching antipsychotics is an effective “rescue”
option, it is costly in personal and economic terms. The optimal
treatment strategy is to begin treatment with the antipsychotic
most likely to lead to effective treatment for each individual
patient.
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OBJECTIVES: To review the literature addressing the economic
consequences of nonadherence in the treatment of schizophre-
nia. This study also seeks to extend the review results to provide
